New Risk • Jun 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Large one-off items impacting financial results. Reported Earnings • May 06
Full year 2026 earnings released: EPS: ₹13.12 (vs ₹3.00 loss in FY 2025) Full year 2026 results: EPS: ₹13.12 (up from ₹3.00 loss in FY 2025). Revenue: ₹34.8b (up 15% from FY 2025). Net income: ₹2.13b (up ₹2.60b from FY 2025). Profit margin: 6.1% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has increased by 116% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 09
Wockhardt Limited Files Marketing Authorisation Application for WCK 5222 with European Medicines Agency Wockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic, WCK 5222, on 5 January 2026. The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countries-Iceland, Liechtenstein, and Norway-covering a total of 30 countries. Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), is eligible for Accelerated Assessment. This pathway allows for an abridged review timeline, reflecting the unmet medical need addressed by the product. The New Drug Application (NDA) on WCK 5222 is already under fast-track review by the US FDA. Based on the comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram negative infections across all countries under the EMA's jurisdiction. The priority review status granted to WCK 5222 underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections. Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation. New Risk • Dec 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 0.09% per year over the past 5 years. Reported Earnings • Nov 04
Second quarter 2026 earnings released: EPS: ₹4.81 (vs ₹1.47 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹4.81 (up from ₹1.47 loss in 2Q 2025). Revenue: ₹8.03b (flat on 2Q 2025). Net income: ₹780.0m (up ₹1.00b from 2Q 2025). Profit margin: 9.7% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 18
Full year 2025 earnings released: ₹3.00 loss per share (vs ₹32.10 loss in FY 2024) Full year 2025 results: ₹3.00 loss per share (improved from ₹32.10 loss in FY 2024). Revenue: ₹30.4b (up 7.2% from FY 2024). Net loss: ₹470.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 17
Wockhardt Limited, Annual General Meeting, Aug 08, 2025 Wockhardt Limited, Annual General Meeting, Aug 08, 2025, at 15:30 Indian Standard Time. New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change). Reported Earnings • May 31
Full year 2025 earnings released: ₹3.02 loss per share (vs ₹32.10 loss in FY 2024) Full year 2025 results: ₹3.02 loss per share (improved from ₹32.10 loss in FY 2024). Revenue: ₹30.7b (up 8.6% from FY 2024). Net loss: ₹470.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 77% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 23
Wockhardt Limited to Report Q4, 2025 Results on May 29, 2025 Wockhardt Limited announced that they will report Q4, 2025 results on May 29, 2025 New Risk • Apr 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 18% per year over the past 5 years. Announcement • Apr 07
Wockhardt Looks to Exit US Generics Biz Wockhardt Limited (NSEI:WOCKPHARMA) is planning to exit the US generics business. Meanwhile, US consumers will have to bear the burden of tariffs, NDTV Profit reported. Habil Khorakiwala, Chairperson of Wockhardt, said, "There is a price pressure on US consumer and healthcare provider in the US. "As far as Wockhardt is concerned, we have around 5% presence in the US and we have planned to exit the US generic business," he said. Commenting on the pharmaceutical industry’s ability to manufacture products in the US, he said, “…will be very, very difficult for pharma to manufacture all products in the US because it will take several years to do that”. This comes amid US President Donald Trump's recent announcement on his administration's intention to impose unprecedented tariffs on pharmaceutical imports, signalling a shift from earlier exemptions under his reciprocal tariff policy. He clarified that pharmaceuticals would be treated as a separate category, with official announcements expected soon. This announcement follows his broader tariff measures, including a 26% duty on Indian imports and a universal 10% tariff on other goods, which were initially exempting pharmaceuticals. Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: ₹0.91 (vs ₹5.75 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹0.91 (up from ₹5.75 loss in 3Q 2024). Revenue: ₹7.29b (up 4.0% from 3Q 2024). Net income: ₹140.0m (up ₹970.0m from 3Q 2024). Profit margin: 1.9% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 03
Wockhardt Limited to Report Q3, 2025 Results on Feb 07, 2025 Wockhardt Limited announced that they will report Q3, 2025 results on Feb 07, 2025 New Risk • Jan 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • Nov 14
Second quarter 2025 earnings released: ₹1.47 loss per share (vs ₹5.37 loss in 2Q 2024) Second quarter 2025 results: ₹1.47 loss per share (improved from ₹5.37 loss in 2Q 2024). Revenue: ₹8.18b (up 8.6% from 2Q 2024). Net loss: ₹220.0m (loss narrowed 71% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings. Announcement • Nov 09
Wockhardt Limited to Report First Half, 2025 Results on Nov 13, 2024 Wockhardt Limited announced that they will report first half, 2025 results on Nov 13, 2024 Announcement • Nov 07
Wockhardt Limited has filed a Follow-on Equity Offering. Wockhardt Limited has filed a Follow-on Equity Offering.
Security Name: Equity Shares
Security Type: Common Stock
Price(minimum): INR 1162.25
Transaction Features: Regulation S; Subsequent Direct Listing Announcement • Oct 12
Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control Organization The Subject Expert Committee (SEC) of Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has provided a favourable recommendation for Wockhardt's novel antibiotic MiqnafTM (nafithromycin) discovered and developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults. The SEC recommendation is based on CDSCO's comprehensive review of product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over last 15 years. A positive opinion from SEC of CDSCO would pave the way for gaining DCGI's final approval for MiqnafTM. MiqnafTM is globally, 1st-ever, Once-a-Day (OD) 3-days-only treatment for CABP patients including those caused by multi-drug resistant (MDR) bugs. The attractive feature of MiqnafTM is that it is highly active against azithromycin and amoxicillin/clavulanate resistant
Pneumococci, as well as entire range of pathogens involved in such infections and thus offering a monotherapy option. Earlier, a lung penetration study conducted in the US
demonstrated best-in-class lung concentrations of MiqnafTM enabling to evolve a convenient, compliance-friendly treatment for respiratory infections. MiqnafTM is expected to play a
significant role in offering a reliable treatment option in the community and thus would obviate the need of hospitalization. Community-acquired pneumonia is the most common infection leading to hospitalization and deaths. Children and older adults are particularly vulnerable. Globally, 2.4 million annual deaths are caused by lower respiratory tract infections. India contributes to 23% of global community pneumonia burden. Announcement • Oct 07
Wockhardt's WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I Study Wockhardt announced advancing the development of several new antibiotics aimed at combating difficult-to-treat drug-resistant bacterial infections that drive anti-microbial resistance (AMR) linked mortality and morbidity. Recently, one of its unique once-a-day, -lactam enhancer based MDR-active antibiotic, WCK 6777 (Ertapenem/Zidebactam) has successfully completed a Phase I study conducted by the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in US. Recognizing the therapeutic potential of WCK 6777 for infections caused by MDR Gram negative pathogens, DMID of NIH had selected this drug for Phase I studies. Zidebactam has already demonstrated promising safety profile in Phase I and on-going Phase II & III studies in combination with Cefepime (WCK 5222). Additionally, recognizing its potential to meet significant unmet medical needs, the US FDA has recently granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI). WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient- parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections. Phase I study of WCK 6777 involved 52 participants and was designed as a double-blind, placebo-controlled, multiple-ascending dose trial in healthy volunteers. The trial rigorously assessed the safety and pharmacokinetics of WCK 6777, administering intravenous doses higher than the anticipated clinical dose over a period of 7 days. Results demonstrated a promising safety profile, with WCK 6777 (up to 3 grams + 3 grams daily) being well-tolerated, and no serious or unexpected adverse events reported. None of the subjects withdrew or were discontinued from the study due to treatment-related adverse events. Pharmacokinetic analysis revealed consistent exposure levels of both ertapenem and zidebactam, with no significant interactions when co-administered daily for the duration of the study. The promising safety data from this study paves the way for the advancement of WCK 6777 into Phase II /III clinical trials. Globally, incidence of UTI were 404.61 million with 236,790 deaths estimated in 2019. It is estimated that 1 in 100 of US adults will experience a cUTI each year, resulting in approximately 2.8 million cUTI cases and annualized total US costs in excess of $6 billion. There are 600,000 hospital admissions among adults for cUTIs each year in the United States with each episode costing an average of $9,441. Emerging therapeutic role of WCK 6777 makes it uniquely positioned to cater to the vast unmet need in the management of infections outside the hospital. About Ertapenem/Zidebactam (WCK 6777): Through independent studies, WCK 6777 is shown to be active against several carbapenem- resistant Gram-negative pathogens such as E. coli and Klebsiella including those producing metallo -lactamases, often encountered in community as well as hospital infections such as urinary tract infections (UTI). Other recently approved antibiotics do not address this issue. Owing to its activity against CDC/WHO/FDA categorized priority pathogens, WCK 6777 was granted a qualified infectious disease product (QIDP) designation in 2020 by U.S. FDA. About Wockhardt's New Drug Discovery portfolio: Over the period of 25 years, Wockhardt has focused its drug discovery efforts in the area of discovering novel medicines for multi-drug resistant infections. This has resulted in a portfolio of 6 products at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA. Wockhardt's flagship novel mechanism based antibiotic, Zaynich (Cepefime/Zidebactam), designed to target extreme-drug resistant Gram negative infections, is undergoing a global Phase 3 study. Zaynich has already saved lives of >35 critically ill patients under compassionate use over last one year and is also being evaluated in a clinical study involving patients with documented meropenem-resistant infections. Clinical and Laboratory Standards Institute (CLSI), US has granted it a susceptibility breakpoint of 64 mg/L for 10 Gram negative pathogens showing high resistance rates, signifying strong potential to cover all the clinically important, extreme drug resistant Gram negative pathogens in seriously ill patients. Reported Earnings • Aug 10
First quarter 2025 earnings released: ₹0.95 loss per share (vs ₹9.28 loss in 1Q 2024) First quarter 2025 results: ₹0.95 loss per share (improved from ₹9.28 loss in 1Q 2024). Revenue: ₹7.69b (up 19% from 1Q 2024). Net loss: ₹140.0m (loss narrowed 90% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Announcement • Aug 05
Wockhardt Limited to Report Q1, 2025 Results on Aug 09, 2024 Wockhardt Limited announced that they will report Q1, 2025 results on Aug 09, 2024 Announcement • May 30
Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) Director Wockhardt Limited announced at the board meeting held on May 28, 2024, approved appointment of Amb. Ahmad Javed (DIN: 08668304) as an Additional (Independent) Director of the Company with effect from 28th May, 2024 and will hold office as an Additional Director of the Company until the upcoming 25th Annual General Meeting of the Company. Amb. Ahmad Javed, aged 68 years, is a distinguished former IPS officer of the 1980 batch Maharashtra cadre and a seasoned diplomat. With a robust educational foundation from St. Stephen's College, Delhi University, he has dedicated nearly four decades to law enforcement and public service. During his stint, Amb. Ahmad served as Commissioner of Police in Solapur City, New Mumbai, and Mumbai, and as Joint Commissioner of Police (Law & Order) in Mumbai. His notable diplomatic tenure includes serving as the Ambassador of India to Saudi Arabia from 2016 to2019. Amb. Ahmad's extensive experience encompasses law and order maintenance, crisis handling and management, Administration & HR, international relations, strategy and policy formulation and conflict resolution. Amb. Ahmad has been honoured with the Police Medal for Meritorious Service, President's Police Medal for Distinguished Service and Director General's Insignia. Currently, he contributes his expertise as an advisor and Independent Director to various organizations. Reported Earnings • May 29
Full year 2024 earnings released: ₹32.05 loss per share (vs ₹38.80 loss in FY 2023) Full year 2024 results: ₹32.05 loss per share (improved from ₹38.80 loss in FY 2023). Revenue: ₹28.8b (up 8.7% from FY 2023). Net loss: ₹4.63b (loss narrowed 17% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • May 23
Wockhardt Limited to Report Q4, 2024 Results on May 28, 2024 Wockhardt Limited announced that they will report Q4, 2024 results on May 28, 2024 Announcement • Apr 04
Wockhardt Limited Announces Cessation of Independent Directors Wockhardt Limited announced that Dr. Sanjaya Baru, Mr. D S Brar and Mr. Aman Mehta ceased to be an Independent Directors of the Company on March 31, 2024, upon completion of their second term of five (5) consecutive years . Announcement • Mar 28
Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion. Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 9,285,163
Price\Range: INR 517
Transaction Features: Regulation S; Subsequent Direct Listing New Risk • Mar 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.6% operating cash flow to total debt). Earnings have declined by 24% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Announcement • Mar 22
Wockhardt Limited has filed a Follow-on Equity Offering. Wockhardt Limited has filed a Follow-on Equity Offering.
Security Name: Equity Shares
Security Type: Common Stock
Transaction Features: Regulation S; Subsequent Direct Listing Reported Earnings • Feb 15
Third quarter 2024 earnings released: ₹5.75 loss per share (vs ₹6.62 loss in 3Q 2023) Third quarter 2024 results: ₹5.75 loss per share (improved from ₹6.62 loss in 3Q 2023). Revenue: ₹7.09b (up 1.4% from 3Q 2023). Net loss: ₹830.0m (loss narrowed 14% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • Nov 15
Second quarter 2024 earnings released: ₹5.37 loss per share (vs ₹13.15 loss in 2Q 2023) Second quarter 2024 results: ₹5.37 loss per share (improved from ₹13.15 loss in 2Q 2023). Revenue: ₹7.77b (up 14% from 2Q 2023). Net loss: ₹770.0m (loss narrowed 59% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Board Change • Sep 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 7 highly experienced directors. Independent Director Amelia Fernandes was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 05
Wockhardt Limited to Report Q1, 2024 Results on Aug 14, 2023 Wockhardt Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Announcement • Jul 24
Wockhardt Limited, Annual General Meeting, Aug 14, 2023 Wockhardt Limited, Annual General Meeting, Aug 14, 2023, at 15:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon; to appoint a Director in place of Ms. Zahabiya Khorakiwala, who retires from office by rotation and, being eligible, offers herself for re-appointment; to consider ratification of remuneration payable to the Cost Auditors for the Financial Year 2023-24; to consider appointment of Ms. Amelia Fernandes as an Independent Director of the Company; to consider approval for re-appointment of Dr. Huzaifa Khorakiwala as an Executive Director and Fixation of Remuneration; and to consider approval for re-appointment of Dr. Murtaza Khorakiwala as Managing Director and Fixation of Remuneration. Announcement • May 20
Wockhardt Limited to Report Q4, 2023 Results on May 26, 2023 Wockhardt Limited announced that they will report Q4, 2023 results on May 26, 2023 Reported Earnings • Feb 14
Third quarter 2023 earnings released: ₹6.62 loss per share (vs ₹0.61 loss in 3Q 2022) Third quarter 2023 results: ₹6.62 loss per share (further deteriorated from ₹0.61 loss in 3Q 2022). Revenue: ₹7.01b (down 18% from 3Q 2022). Net loss: ₹960.0m (loss widened ₹892.2m from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Announcement • Feb 04
Wockhardt Limited to Report Q3, 2023 Results on Feb 13, 2023 Wockhardt Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 7 highly experienced directors. Additional Non-Executive Independent Director Akhil Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 06
Second quarter 2023 earnings released: ₹13.15 loss per share (vs ₹3.03 profit in 2Q 2022) Second quarter 2023 results: ₹13.15 loss per share (down from ₹3.03 profit in 2Q 2022). Revenue: ₹7.36b (down 15% from 2Q 2022). Net loss: ₹1.89b (down ₹2.23b from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year. Reported Earnings • Jun 02
Full year 2022 earnings released Full year 2022 results: Revenue: (down 100% from FY 2021). Net income: (up ₹2.99b from FY 2021). Profit margin: (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Board Change • Jun 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Director Akhil Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 01
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: ₹0.61 loss per share (down from ₹1.38 profit in 3Q 2021). Revenue: ₹8.56b (up 12% from 3Q 2021). Net loss: ₹67.8m (down 145% from profit in 3Q 2021). Revenue missed analyst estimates by 7.3%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 11
Second quarter 2022 earnings released: EPS ₹3.03 (vs ₹0.32 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹8.62b (up 21% from 2Q 2021). Net income: ₹335.3m (up ₹299.8m from 2Q 2021). Profit margin: 3.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 02
Board Member recently bought ₹4.4m worth of stock On the 25th of August, Akhilesh Krishna Gupta bought around 10k shares on-market at roughly ₹439 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹22m more in shares than they bought in the last 12 months. Executive Departure • Jul 23
Company Secretary & Compliance Officer Gajanand Sahu has left the company On the 22nd of July, Gajanand Sahu's tenure as Company Secretary & Compliance Officer ended after 1.2 years in the role. We don't have any record of a personal shareholding under Gajanand's name. Gajanand is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.38 years. Reported Earnings • Jul 10
Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: ₹27.1b (down 4.8% from FY 2020). Net loss: ₹2.99b (loss widened 83% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jun 18
Insider recently sold ₹20m worth of stock On the 14th of June, Mahesh Patel sold around 30k shares on-market at roughly ₹658 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months. Reported Earnings • May 30
Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020) The company reported a poor full year result with increased losses and weaker control over costs, although revenues were flat. Full year 2021 results: Revenue: ₹28.4b (flat on FY 2020). Net loss: ₹2.99b (loss widened 83% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Jan 30
Third quarter 2021 earnings released: EPS ₹1.38 (vs ₹0.87 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: ₹8.65b (flat on 3Q 2020). Net income: ₹152.4m (up 58% from 3Q 2020). Profit margin: 1.8% (up from 1.1% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Dec 30
New 90-day high: ₹551 The company is up 82% from its price of ₹303 on 01 October 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Recent Insider Transactions • Dec 17
Insider recently sold ₹1.6m worth of stock On the 11th of December, Mahesh Patel sold around 3k shares on-market at roughly ₹536 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Is New 90 Day High Low • Dec 08
New 90-day high: ₹487 The company is up 73% from its price of ₹281 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. Is New 90 Day High Low • Nov 20
New 90-day high: ₹393 The company is up 22% from its price of ₹322 on 21 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.